Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Xiaoyi Yin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4154-2044; OpenAlex author ID A5102750186. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2021: 2 papers · 2022: 2 papers · 2023: 5 papers · 2024: none · 2025: 6 papers · 2026: 4 papers

Papers 19

  1. The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant therapy. Co-author DOI 10.1016/j.canlet.2026.218252↗
  2. Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post- neoadjuvant therapy" [Cancer Lett. (202… Co-author DOI 10.1016/j.canlet.2026.218298↗
  3. T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial. Co-author DOI 10.1016/j.ymthe.2026.03.012↗
  4. Early-Onset Pancreatic Ductal Adenocarcinoma: Clinical Features, Genomic Landscape, and Treatment-Mediated Survival Advantage Co-author DOI 10.21203/rs.3.rs-9647757/v1↗
  5. Periarterial divestment following neoadjuvant therapy in patients with locally advanced pancreatic cancer with celiac axis invasion: A safe and effective surgi… Co-author DOI 10.1016/j.surg.2024.109045↗
  6. A practical distribution pattern of α-SMA-positive carcinoma associated fibroblasts indicates poor prognosis of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102282↗
  7. Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. Co-author DOI 10.1038/s41467-025-57520-3↗
  8. Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. Co-author DOI 10.1172/jci.insight.181873↗
  9. Senescence-driven molecular subtyping in pancreatic cancer: a multi-omics framework for precision medicine. Co-author DOI 10.1186/s12885-025-15341-z↗
  10. A mitochondria-related gene-based signature predicts pancreatic ductal adenocarcinoma clinical outcome and revealed CAMK2A/THEM4 regulates progression phenotyp… Co-author DOI 10.1186/s12967-025-07456-5↗
  11. Risk factors of positive resection margin differ in pancreaticoduodenectomy and distal pancreatosplenectomy for pancreatic ductal adenocarcinoma undergoing upf… Co-author DOI 10.1016/j.asjsur.2022.09.156↗
  12. Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. First author DOI 10.1093/bjs/znac457↗
  13. A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-023-11181-x↗
  14. Combined utility of Ki-67 index and tumor grade to stratify patients with pancreatic ductal adenocarcinoma who underwent upfront surgery. First author DOI 10.1186/s12893-023-02256-4↗
  15. Systemic Immune-Inflammation Index After Neoadjuvant Therapy Predicts the Pathological Response in Patients with Resected Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-2856912/v1↗
  16. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases. Co-author DOI 10.1016/j.ijsu.2022.106786↗
  17. Negative p53 Expression Confers Worse Prognosis in Patients With Resected Pancreatic Ductal Adenocarcinoma: Research Focused on Reinterpretation of Immunohisto… Co-author DOI 10.1097/mpa.0000000000002175↗
  18. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08380-9↗
  19. Risk Factors of Positive Resection Margin Differ in Pancreaticoduodenectomy and Distal Pancreatosplenectomy For Pancreatic Ductal Adenocarcinoma: A Study Based… Co-author DOI 10.21203/rs.3.rs-963631/v1↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gang Jin · 15 shared papers, 2021–2026 · strength 2.84
  2. Xiaohan Shi · 13 shared papers, 2021–2026 · strength 2.26
  3. Shiwei Guo · 13 shared papers, 2021–2026 · strength 2.21
  4. Suizhi Gao · 13 shared papers, 2021–2026 · strength 2.16
  5. Kailian Zheng · 11 shared papers, 2022–2026 · strength 1.97
  6. Guoxiao Zhang · 10 shared papers, 2021–2026 · strength 1.78
  7. Xiongfei Xu · 9 shared papers, 2021–2026 · strength 1.59
  8. Lingyu Zhu · 7 shared papers, 2023–2026 · strength 1.24
  9. Bo Li · 5 shared papers, 2021–2023 · strength 0.77
  10. Meilong Shi · 4 shared papers, 2025 · strength 0.77
  11. Yunguang Li · 4 shared papers, 2025–2026 · strength 0.74
  12. Shuo Shen · 5 shared papers, 2021–2023 · strength 0.71
  13. Gang Li · 4 shared papers, 2021–2025 · strength 0.59
  14. Meilong Shi · 3 shared papers, 2026 · strength 0.59
  15. Huan Wang · 2 shared papers, 2026 · strength 0.55
  16. Bin Song · 3 shared papers, 2023–2025 · strength 0.49
  17. Jian Wang · 3 shared papers, 2022–2023 · strength 0.45
  18. Zhendong Fu · 2 shared papers, 2025 · strength 0.40
  19. Yehan Zhang · 2 shared papers, 2026 · strength 0.39
  20. Eric Tran · 2 shared papers, 2025–2026 · strength 0.39
  21. Gang Y Jin · 2 shared papers, 2023–2025 · strength 0.37
  22. Dong Gao · 2 shared papers, 2025 · strength 0.35
  23. Gang Jin · 2 shared papers, 2022–2025 · strength 0.33
  24. Bo Li · 2 shared papers, 2022–2025 · strength 0.32
  25. Chenming Ni · 2 shared papers, 2021–2023 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.